Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobiological disorder exhibited by difficulty maintaining attention, as well as hyperactivity and impulsive behavior. Central nervous system (CNS) stimulants are the first line of treatment for ADHD. With the increase in number of adults on CNS stimulants, the question that arises is how well do we understand the long-term cardiovascular effects of these drugs. There has been increasing concern that adults with ADHD are at greater risk for developing adverse cardiovascular events such as sudden death, myocardial infarction, and stroke as compared to pediatric population. Cardiovascular response attributed to ADHD medication has mainly been observed in heart rate and blood press...
Adderall, consisting of a mixture of amphetamine salts and dextroamphetamine salts, is a prescriptio...
OBJECTIVE: To examine available literature regarding attention deficit hyperactivity disorder (ADHD)...
The risk for adverse cardiac events in subjects between 3 and 20 years of age treated with methylphe...
Compared to children, adults with ADHD are at greater risk for developing adverse cardiovascular rel...
CONTEXT: More than 1.5 million US adults use stimulants and other medications labeled for treatment ...
Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder that is often t...
Abstract Background There is increasing concern that prescription stimulants may be associated with ...
Objective: To examine the naturalistic response to and cardiovascular side effects of stimulant medi...
Researchers from Vanderbilt University, TN; Kaiser Permanente, California; and other centers conduct...
Accumulating evidence suggests a higher risk for cardiovascular diseases among individuals with ment...
Although the prevalence of attention-deficit/hyperactivity disorder (ADHD) has been stable over the ...
ABSTRACT The purpose of this article is to examine the association of adverse cardiovascular risks w...
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with onset usually ...
BACKGROUND: Many children and adolescents with attention deficit/hyperactivity disorder (ADHD) are t...
Background: Many children and adolescents with attention deficit/hyperactivity disorder (ADHD) are t...
Adderall, consisting of a mixture of amphetamine salts and dextroamphetamine salts, is a prescriptio...
OBJECTIVE: To examine available literature regarding attention deficit hyperactivity disorder (ADHD)...
The risk for adverse cardiac events in subjects between 3 and 20 years of age treated with methylphe...
Compared to children, adults with ADHD are at greater risk for developing adverse cardiovascular rel...
CONTEXT: More than 1.5 million US adults use stimulants and other medications labeled for treatment ...
Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder that is often t...
Abstract Background There is increasing concern that prescription stimulants may be associated with ...
Objective: To examine the naturalistic response to and cardiovascular side effects of stimulant medi...
Researchers from Vanderbilt University, TN; Kaiser Permanente, California; and other centers conduct...
Accumulating evidence suggests a higher risk for cardiovascular diseases among individuals with ment...
Although the prevalence of attention-deficit/hyperactivity disorder (ADHD) has been stable over the ...
ABSTRACT The purpose of this article is to examine the association of adverse cardiovascular risks w...
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with onset usually ...
BACKGROUND: Many children and adolescents with attention deficit/hyperactivity disorder (ADHD) are t...
Background: Many children and adolescents with attention deficit/hyperactivity disorder (ADHD) are t...
Adderall, consisting of a mixture of amphetamine salts and dextroamphetamine salts, is a prescriptio...
OBJECTIVE: To examine available literature regarding attention deficit hyperactivity disorder (ADHD)...
The risk for adverse cardiac events in subjects between 3 and 20 years of age treated with methylphe...